AUTHOR=Yu Xingxing , Wang Xin , Wang Xu , Zhou Yi , Li Yanchun , Wang Aiwei , Wang Tongtong , An Yihan , Sun Weidong , Du Jing , Tong Xiangmin , Wang Ying TITLE=TEOA Inhibits Proliferation and Induces DNA Damage of Diffuse Large B-Cell Lymphoma Cells Through Activation of the ROS-Dependent p38 MAPK Signaling Pathway JOURNAL=Frontiers in Pharmacology VOLUME=11 YEAR=2020 URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.554736 DOI=10.3389/fphar.2020.554736 ISSN=1663-9812 ABSTRACT=
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of lymphoma, accounting for approximately 30% to 40% of non-Hodgkin’s lymphomas (NHL). The administration of rituximab significantly improved the outcomes of DLBCL; however, the unavoidable development of resistance limits the long-term efficacy. Therefore, a new generation of less toxic drugs with higher chemotherapy response is required to prevent or reverse chemoresistance. TEOA is a pentacyclic triterpenoid compound isolated from the roots of